American Journal of Physiology-Cell Physiology · 1982 · 151 citations · 15 references
Porcine Kidney CellsNa+-dependent Hexose TransportCell ProliferationCytoskeletonCell GrowthCellular PhysiologyTumor BiologyCultured LineCell RegulationReceptor Tyrosine KinaseMembrane TransportCell SignalingLlc-pk1 CellsAlpha-meg Concentrating CapacityAnimal PhysiologyHealth SciencesCell PhysiologyMolecular PhysiologyXenotransplantationProtein TransportPharmacologyCell BiologyTumor MicroenvironmentDevelopmental BiologyPhysiologyMetabolismMedicineTumor PromoterKidney ResearchExtracellular Matrix
LLC-PK1 cells in culture do not concentrate alpha-methylglucoside (alpha-meG) during their early growth phase but develop the capacity to concentrate this hexose as the growth rate decreases in confluent cultures. The concentrating ability is dependent on the Na+ electrochemical gradient and is inhibited by phlorizin with KI,0.5 approximately 0.2 microM. The development of the concentrative capacity can be accelerated by the Friend cell inducer hexamethylene bisacetamide (HMBA) and by the phosphodiesterase inhibitors dibutyryl cAMP, theophylline, and 1-methyl-3-isobutylxanthine (MIX). In cultures treated with any of these differentiation-accelerating chemicals, the development of alpha-meG concentrating capacity is severely inhibited by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) but not by inactive (in tumor promotion) analogs of TPA. In all cases, an early event in the development of alpha-meG accumulating capacity is an elevated intracellular cAMP concentration; however the results suggest that this increase in cAMP may be necessary but not sufficient to induce the differentiated hexose-accumulating capacity.
15